The UAB Center for AIDS Research (CFAR) is a designated University-wide Center with department-level status, and is governed by a Constitution and By-Laws. The overall goal of the UAB CFAR is to stimulate and support multidisciplinary basic, behavioral and clinical AIDS research so as to hasten the development of effective treatments and prevention strategies for AIDS. The major objectives of the Center for AIDS Research are threefold: 1.To enhance ongoing outstanding research programs by facilitating interdisciplinary interactions, providing critical shared resource facilities, and providing administrative and fiscal management support mechanisms for Center investigators. 2.To stimulate the entry of junior and established faculty into HIV/AIDS research programs. This will be accomplished through mentoring and training of young investigators and by the continuation of a peer-reviewed, competitive Developmental Grant Program. 3. To stimulate recruitment and program development efforts in AIDS-related areas. The Center will assist Departments and Divisions in the process of investigator recruitment. These approaches will ensure continued growth and development of AIDS-related research in the CFAR. Scientific leadership and management are provided by the Director, Eric Hunter, Ph.D., and an Executive Committee of 8 senior faculty, aided by External and Internal Advisory Committees. The Center has 131 Center members from 28 Divisions and Departments within the University funded by AIDS-related grants and contracts totaling more than $68 million in research support. Ten Core Facilities are proposed that will provide key support for the Center's principal thematic areas of viral pathogenesis, experimental therapeutics, and vaccine development. From 1997-2002 the CFAR has fostered recruitment of more than 20 investigators into the field and garnered strong Institutional support. All of the major research efforts within the Center link basic and clinical/behavioral research, and together they utilize every shared facility supported by the CFAR Core grant.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027767-20
Application #
7236040
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1988-03-30
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2009-02-28
Support Year
20
Fiscal Year
2007
Total Cost
$1,732,341
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Stafman, Laura L; Mruthyunjayappa, Smitha; Waters, Alicia M et al. (2018) Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget 9:22665-22679
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145

Showing the most recent 10 out of 955 publications